Trial Profile
A Dose-Ranging Study of GSK189075 versus Placebo in the treatment of Type 2 Diabetes Mellitus in Subjects taking Metformin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Remogliflozin etabonate (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors GSK
- 03 Apr 2022 Status changed from recruiting to completed.
- 26 Mar 2022 This trial has been completed in Belgium (End Date: 23 Nov 2006), according to European Clinical Trials Database record.
- 26 May 2011 New trial record